Terbinafine is an antifungal drug that works by blocking an enzyme essential to fungal survival, making it one of the most widely prescribed treatments for dermatophyte infections of the skin, hair, and nails. First discovered in 1983 and approved in the United States in 1996, terbinafine belongs to the allylamine class of antifungals and is available in both oral and topical forms.1PubMed Central. New microbial source of the antifungal allylamine “Terbinafine” Its clinical track record spans decades and millions of prescriptions, but the drug carries pharmacological nuances that matter for both prescribers and patients.
How Terbinafine Kills Fungi
Terbinafine targets an enzyme called squalene epoxidase, which fungi need to produce ergosterol. Ergosterol is a structural component of the fungal cell membrane, roughly analogous to what cholesterol does in human cells. When terbinafine blocks this enzyme, two things happen simultaneously: the fungus runs out of ergosterol, weakening its cell membrane, and squalene (the precursor molecule) piles up to toxic levels inside the cell.2PubMed. Terbinafine: mode of action and properties of the squalene epoxidase inhibition This dual hit is what makes terbinafine primarily fungicidal rather than merely fungistatic. Instead of just slowing fungal growth, it actively kills the organism.
Molecular modeling work has shown that terbinafine doesn’t compete directly with the natural substrate for the enzyme’s active site. Instead, it changes the shape of the enzyme so the substrate can no longer bind, a mechanism described as noncompetitive inhibition.3PubMed. Detailed mechanism of squalene epoxidase inhibition by terbinafine This distinction matters clinically because it means the drug remains effective even when large amounts of the natural substrate are present. The toxic squalene accumulation and ergosterol depletion together create conditions incompatible with fungal survival.4PubMed. Pharmacokinetics and pharmacology of terbinafine and itraconazole
Getting to Where the Infection Lives
One of terbinafine’s most useful pharmacological features is how readily it reaches the tissues where fungal infections actually sit. The drug is highly lipophilic, meaning it dissolves well in fats. After you swallow a tablet, terbinafine concentrates in the outermost layer of the skin, in sebum (skin oil), and in the nail plate. It penetrates keratinizing tissue extremely well, accumulating in nails and skin over time.5Journal of the American Academy of Dermatology. Pharmacokinetics and pharmacology of terbinafine and itraconazole – Section: TERBINAFINE: A PHARMACOLOGIC PROFILE This is why oral terbinafine continues to work for weeks or even months after you stop taking it. The drug is already embedded in the keratin of your nails and skin, where it persists long enough to outlast the fungal infection.
Terbinafine is primarily cleared through the kidneys, with about 80% of the drug excreted in urine.6PubMed Central. Retrospective Cohort Study of Hepatic and Hematologic Toxicity in Terbinafine-Treated Onychomycosis Patients With Reduced Kidney Function at an Academic Institution – Section: Discussion This renal dependence becomes relevant for people with reduced kidney function, a point covered later in the article.
Nail Infections and Why Terbinafine Dominates Treatment
Toenail fungus (onychomycosis) is the condition most commonly associated with oral terbinafine therapy, and the evidence here is strong. A standard course of 250 mg per day generally achieves a lab-confirmed cure in more than 80% of patients.7PubMed. Terbinafine. An update of its use in superficial mycoses In head-to-head trials against itraconazole, the other major oral antifungal used for nail infections, terbinafine has consistently come out ahead. One controlled trial found lab-confirmed cure rates of 81% for terbinafine versus 63% for itraconazole, with 92% of terbinafine-treated patients having negative cultures at study’s end compared to 67% on itraconazole.8PubMed. Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails
A meta-analysis of the published worldwide literature confirmed this advantage, finding that terbinafine is significantly more effective than itraconazole at achieving lab-confirmed cure of toenail infections.9Journal of Cutaneous Medicine and Surgery. Terbinafine Is More Effective Than Itraconazole In Treating Toenail Onychomycosis: Results from a Meta-analysis of Randomized Controlled Trials Perhaps more telling than the initial cure rates is what happens over time. A five-year follow-up study found that roughly half of terbinafine-treated patients maintained their cure without needing retreatment, compared to only about one in eight itraconazole-treated patients. Relapse rates told the same story: 23% relapsed after terbinafine versus 53% after itraconazole.10JAMA Dermatology. Long-term Effectiveness of Treatment With Terbinafine vs Itraconazole in Onychomycosis: A 5-Year Blinded Prospective Follow-up Study – Section: Results
Non-dermatophyte molds can also cause nail infections, though less frequently. For these cases, terbinafine’s advantage narrows. One study comparing the two drugs for non-dermatophyte mold infections found similar cure rates: about 70% for terbinafine and 68% for itraconazole, with no statistically significant difference between them.11PubMed. Continuous terbinafine and pulse itraconazole for the treatment of non-dermatophyte mold toenail onychomycosis
Skin and Scalp Infections
Terbinafine’s usefulness extends well beyond nails. Topical formulations (typically 1% cream or solution) applied once or twice daily for up to two weeks achieve lab-confirmed cure in more than 80% of patients with common skin fungal infections like athlete’s foot, jock itch, and ringworm.7PubMed. Terbinafine. An update of its use in superficial mycoses A Cochrane review of topical antifungal treatments for jock itch and ringworm found that patients treated with terbinafine were roughly four and a half times more likely to achieve clinical cure than those given a placebo.12Cochrane Database of Systematic Reviews. Topical antifungal treatments for tinea cruris and tinea corporis – Section: Abstract
Scalp ringworm (tinea capitis), primarily a childhood infection, is more complicated. The response depends heavily on which species is causing it. For infections caused by Trichophyton species, terbinafine works well with short courses. In one study, two weeks of treatment cured 86% of Trichophyton scalp infections. But for Microsporum species, two weeks was nowhere near enough. None of the patients with Microsporum infections responded to two weeks of therapy; it took four weeks or more to start seeing cures.13PubMed. Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species
A Cochrane review comparing systemic antifungals for scalp ringworm in children reinforced this species-dependent split. Terbinafine outperformed griseofulvin (the traditional standard) for Trichophyton tonsurans infections, but griseofulvin was actually the better choice for Microsporum infections.14PubMed. Systemic antifungal therapy for tinea capitis in children: An abridged Cochrane Review The practical takeaway is that identifying the infecting species matters. Terbinafine is approved for treating scalp ringworm in children in many countries and generally provides good cure rates for Trichophyton infections using shorter courses than griseofulvin requires.15PubMed. The efficacy and safety of terbinafine in children
Side Effects That Matter
For most patients, oral terbinafine is well tolerated, with gastrointestinal complaints (nausea, mild abdominal discomfort, diarrhea) being the most common side effects. But a few adverse reactions deserve attention because they can be serious, unusual, or easy to miss.
Taste Disturbance
Terbinafine has a distinctive association with taste changes, or dysgeusia. This is recognized as an uncommon side effect, but when it happens, the experience can be profoundly disruptive. Patients typically describe a persistent metallic taste, a marked aversion to sweet foods, and sometimes a near-complete loss of flavor perception.16PubMed Central. Severe dysgeusia and weight loss associated with terbinafine use: A case report Objective testing in affected patients has confirmed that taste perception for sweet, sour, and bitter stimuli is significantly depressed across both the front and back of the tongue, while the sense of smell remains normal.17PubMed. Objective assessment of terbinafine-induced taste loss In most cases the taste loss resolves after the drug is stopped, but recovery can take weeks to months. In severe cases, the loss of appetite and food aversion can lead to significant unintentional weight loss before the connection to the medication is recognized.
Liver Injury
Liver damage is rare but is the most medically serious risk associated with oral terbinafine. The estimated incidence of hepatobiliary dysfunction is about 1 in 45,000 prescriptions.18PubMed. Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity When it occurs, the presentation can include jaundice, abdominal pain, itching, and pale stools. One published case involved a 41-year-old man who developed worsening jaundice and cholestasis (bile flow obstruction) after starting terbinafine for a nail infection, requiring hospitalization and a liver biopsy to confirm the drug as the cause.19PubMed Central. Drug-Induced Liver Injury Secondary to Terbinafine Use Terbinafine is often considered contraindicated in people with existing liver disease because of this hepatotoxic potential.20PubMed Central. Terbinafine used safely in autoimmune hepatitis for treatment of tinea corporis Prescribers routinely order baseline liver function tests before starting oral terbinafine and may repeat them during therapy.
Rare Immune and Blood-Related Reactions
A handful of case reports have linked terbinafine to drug-induced lupus, a syndrome resembling autoimmune lupus but triggered by a medication. This can range from skin-limited disease (subacute cutaneous lupus) to more severe forms involving the kidneys. Four cases of subacute cutaneous lupus during terbinafine therapy for nail infections have been reported,21Journal of the American Academy of Dermatology. Reports Terbinafine-induced subacute cutaneous lupus erythematosus and terbinafine has been classified as carrying a relatively high risk among drugs known to induce this form of lupus.22PubMed. Terbinafine : Drug-induced lupus erythematodes and triggering of psoriatic skin lesions In one extreme case, a 22-year-old man with no prior medical history developed fever, rash, joint pain, and progressive kidney failure weeks after starting terbinafine, ultimately diagnosed with lupus nephritis requiring renal biopsy.23PubMed Central. Terbinafine Induced Lupus Erythematosus With Progression to Lupus Nephritis
Agranulocytosis, a dangerous drop in a type of white blood cell, has also been reported. A pediatric case documented the reaction appearing four weeks into treatment and resolving within a week of stopping the drug, mirroring the pattern seen in adult reports.24PubMed. Reversible agranulocytosis associated with oral terbinafine in a pediatric patient These immune reactions are exceedingly rare, but they underline why any unexplained fever, rash, or joint symptoms during terbinafine therapy warrant prompt medical attention.
The CYP2D6 Problem and Drug Interactions
Terbinafine is a potent inhibitor of CYP2D6, a liver enzyme responsible for breaking down a wide range of other medications. This is not an obscure academic detail. CYP2D6 metabolizes many common drugs, including certain antidepressants, beta-blockers, and opioids. When terbinafine blocks this enzyme, blood levels of co-administered drugs can rise dramatically.
The interaction has been studied rigorously with tricyclic antidepressants. In healthy volunteers, terbinafine roughly doubled the peak blood level and increased overall drug exposure nearly fivefold for desipramine, a tricyclic antidepressant cleared through CYP2D6.25PubMed. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers What makes this interaction especially tricky is its persistence. Blood levels of the affected drug were still elevated four weeks after terbinafine was stopped. Modeling studies predict that for nortriptyline (another tricyclic), blood concentrations can exceed the toxic threshold during co-administration and remain about 50% higher than normal even six months after stopping terbinafine.26PubMed. Analysis of the Mechanism of Prolonged Persistence of Drug Interaction between Terbinafine and Amitriptyline or Nortriptyline
This prolonged interaction is driven by terbinafine’s long half-life in tissues. Even after the last pill, the drug and its metabolites linger in the body and continue suppressing CYP2D6 activity. Anyone taking medications metabolized by this enzyme should have a careful conversation with their prescriber before starting terbinafine. The interaction does not just apply to antidepressants; codeine, tamoxifen, and several cardiac drugs are also CYP2D6 substrates.
Emerging Resistance
For decades, terbinafine resistance in dermatophytes was essentially unheard of. That has changed. Reports from India initially drew attention to terbinafine-resistant strains of Trichophyton, and the problem is no longer geographically confined. A study of dermatophyte isolates from toenail infections in the United States found that about 3.7% of Trichophyton species carried mutations in the squalene epoxidase gene, the very target terbinafine attacks.27PubMed. Detection of Squalene Epoxidase Mutations in United States Patients with Onychomycosis: Implications for Management
Multiple specific mutations have been identified. European research documented several amino acid substitutions in resistant strains that were absent in susceptible controls.28PubMed Central. Emerging Terbinafine Resistance in Trichophyton: Clinical Characteristics, Squalene Epoxidase Gene Mutations, and a Reliable EUCAST Method for Detection Recently, researchers provided the first direct genetic proof that one common mutation, Leu393Phe, actually causes resistance rather than just being associated with it. When this single mutation was introduced into a susceptible strain of Trichophyton rubrum in the laboratory, the fungus became more than 8,000 times more resistant to terbinafine.29PubMed. Genetic confirmation of terbinafine resistance in Trichophyton rubrum mediated by the squalene epoxidase Leu393Phe mutation via targeted gene replacement
While resistance rates remain relatively low in most regions, the trend is concerning given that terbinafine is the most commonly used oral antifungal for dermatophyte infections worldwide. If a patient completes a full course and the infection stubbornly persists, resistance should be on the differential diagnosis alongside incomplete adherence or reinfection.
Topical Versus Oral and the New High-Concentration Formulation
Standard topical terbinafine (1% cream or solution) works well for superficial skin infections but has historically been inadequate for nail disease. Nails are dense and poorly penetrated by a cream rubbed on the surface, and topical therapy for onychomycosis generally requires months of daily application with lower cure rates than oral treatment.30PubMed. Pharmacokinetics of antifungal agents in onychomycoses The trade-off is that topical formulations avoid the systemic side effects and drug interactions associated with oral use.
A newer approach tries to bridge this gap. A topical terbinafine 10% solution (MOB015B) has been developed to deliver higher local drug concentrations into the nail. In a phase 1 trial, this formulation produced systemic blood levels roughly 2,000 times lower than those seen after four weeks of oral terbinafine, suggesting a very wide safety margin against systemic toxicity.31PubMed Central. Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis Whether this translates into clinical cure rates approaching those of oral therapy is something later-phase trials will need to establish, but the pharmacokinetic profile is encouraging for patients who cannot or prefer not to take the oral form.
Kidney Disease and Dose Adjustments
Because terbinafine depends heavily on renal clearance, reduced kidney function logically raises the question of whether the dose should be lowered. Some experts have suggested halving the daily dose for patients with creatinine clearance below 50 mL/min. However, the prescribing information does not specifically mandate this, and supporting data are scarce. A small retrospective study of 13 kidney transplant recipients treated with the standard 250 mg daily dose for 12 weeks found no liver or blood abnormalities, suggesting the drug may be safe even in patients with substantially reduced kidney function.6PubMed Central. Retrospective Cohort Study of Hepatic and Hematologic Toxicity in Terbinafine-Treated Onychomycosis Patients With Reduced Kidney Function at an Academic Institution – Section: Discussion Still, the evidence base is thin enough that caution and close monitoring remain reasonable for this population.
Cost Comparisons
Cost matters for nail infections because treatment courses are long (typically 6 weeks for fingernails, 12 weeks for toenails) and recurrence is common enough that some patients go through multiple rounds. Older cost-effectiveness analyses found that terbinafine consistently beat itraconazole on economic grounds, partly because it was cheaper per course and partly because its higher cure and lower relapse rates meant fewer retreatments. One analysis calculated total treatment costs of roughly $700 for terbinafine versus roughly $1,200 for itraconazole, with the cost per disease-free day significantly lower for terbinafine.32PubMed. Cost-effectiveness of two new treatments for onychomycosis: an analysis of two comparative clinical trials Generic terbinafine is now widely available, which has further lowered the drug acquisition cost.33PubMed. Onychomycosis. Treatment, quality of life, and economic issues
Uses Beyond Dermatophytes
Terbinafine’s activity is strongest against dermatophytes, but researchers have explored its potential against a wider range of fungal and even parasitic organisms. Limited clinical data suggest that terbinafine is a useful first-line treatment for chromoblastomycosis (a chronic skin infection caused by dematiaceous fungi) and shows activity against pulmonary aspergillosis. There are also preliminary data hinting at efficacy in histoplasmosis, Pneumocystis infection, fungal mycetoma, and cutaneous leishmaniasis, a parasitic disease.34PubMed. Therapeutic potential of terbinafine in subcutaneous and systemic mycoses
In laboratory testing, terbinafine shows strong inhibition of dermatophytes but intermediate or poor activity against certain other organisms. Fusarium species, which can cause stubborn nail and skin infections, are essentially resistant. Candida parapsilosis shows intermediate sensitivity, and Scytalidium hyalinum falls in between.35Anais Brasileiros de Dermatologia. Evaluation of the disk-diffusion method to determine the in vitro efficacy of terbinafine against subcutaneous and superficial mycoses agents – Section: RESULTS These laboratory susceptibility profiles help explain why terbinafine is the go-to drug for classic dermatophyte infections but not necessarily the right choice when a different organism is responsible. Identifying the pathogen, whether through culture or molecular methods, becomes especially important when an infection fails to respond to standard therapy or when the clinical picture is atypical.